D-0249-2019 Class III Terminated

Recalled by Amerigen Pharmaceuticals Inc. — Lyndhurst, NJ

FDA drug recall D-0249-2019 was initiated by Amerigen Pharmaceuticals Inc. on Oct 5, 2018 and is designated Class III. Reason for recall: Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing. The recall status is terminated (terminated Sep 30, 2019). Affected quantity: 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 24, 2018
Initiation Date
Oct 5, 2018
Termination Date
Sep 30, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,232 bottles: a) 4,146 bottles; b) 1,086 bottles

Product description

Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.

Reason for recall

Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.

Distribution pattern

Product was distributed U.S. nationwide.

Code information

Lot #: a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0249-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0249-2019. Report a data issue: hello@regdatalab.com.